The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes.

Curtis L Triplitt, Janet B. McGill, Daniel Porte, Christopher S. Conner

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

BACKGROUND: The prevalence of diabetes is growing in the United States and, for many patients, blood glucose continues to be poorly managed. Significantly, more than half of people with type 2 diabetes mellitus (T2DM) have hemoglobin A1Cs greater than 7%. Several factors contribute to the failure to achieve treatment goals, including clinical inertia (the failure to initiate or advance therapy in a patient who is not at the evidence-based therapeutic goal) and failure to address all components of disease pathophysiology. Newer classes of antihyperglycemic agents, the incretin-based therapies, have the potential to improve goal achievement. OBJECTIVE: To review incretin physiology and the latest clinical data on glucagon-like peptide-1 (GLP-1) mimetics and dipeptidyl peptidase-IV (DPP-4) inhibitors and to use this as a foundation to discuss the practical issues of disease management, including clinical inertia, clinical recommendations, and evaluation of the best fit for incretin-based therapies in current treatment paradigms. SUMMARY: Clinical inertia is an important contributing factor to T2DM treatment failure and may be improved through more specific diagnosis, more complete patient education, and an emphasis on earlier and more aggressive therapy in goal-oriented fashion. Based largely on the underlying pathophysiology of T2DM, newer ACE/AACE guidelines have been developed to facilitate this more aggressive approach. The incretin-based therapies can favorably impact some underlying elements in T2DM pathophysiology, including glucagon hypersecretion, rapid gastric emptying, postprandial hyperglycemia, and, possibly, chronic -cell dysfunction. When incorporated early into a long-term, treat-to-target management plan, incretin-based therapies have the potential to reduce the prevalence of treatment failure in T2DM and may positively impact disease progression. CONCLUSIONS: Clinicians need to recognize and address the scope and impact of clinical inertia on T2DM patient outcomes. Better use of conventional treatment options and/or consideration of newer incretin-based therapies can contribute to improvements in patient health.

Original languageEnglish (US)
JournalJournal of managed care pharmacy : JMCP
Volume13
Issue number9 Suppl C
StatePublished - Dec 2007
Externally publishedYes

Fingerprint

Incretins
Managed Care Programs
Medical problems
Type 2 Diabetes Mellitus
Therapeutics
Dipeptidyl Peptidase 4
Treatment Failure
Glucagon-Like Peptide 1
Physiology
Glucagon
Hypoglycemic Agents
Blood Glucose
Hemoglobins
Education
Health
Gastric Emptying
Patient Education
Disease Management
Hyperglycemia
Disease Progression

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Health Policy
  • Pharmacy

Cite this

The changing landscape of type 2 diabetes : the role of incretin-based therapies in managed care outcomes. / Triplitt, Curtis L; McGill, Janet B.; Porte, Daniel; Conner, Christopher S.

In: Journal of managed care pharmacy : JMCP, Vol. 13, No. 9 Suppl C, 12.2007.

Research output: Contribution to journalArticle

Triplitt, Curtis L ; McGill, Janet B. ; Porte, Daniel ; Conner, Christopher S. / The changing landscape of type 2 diabetes : the role of incretin-based therapies in managed care outcomes. In: Journal of managed care pharmacy : JMCP. 2007 ; Vol. 13, No. 9 Suppl C.
@article{e55f1b58ca1e4dbb985e93f474045bc5,
title = "The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes.",
abstract = "BACKGROUND: The prevalence of diabetes is growing in the United States and, for many patients, blood glucose continues to be poorly managed. Significantly, more than half of people with type 2 diabetes mellitus (T2DM) have hemoglobin A1Cs greater than 7{\%}. Several factors contribute to the failure to achieve treatment goals, including clinical inertia (the failure to initiate or advance therapy in a patient who is not at the evidence-based therapeutic goal) and failure to address all components of disease pathophysiology. Newer classes of antihyperglycemic agents, the incretin-based therapies, have the potential to improve goal achievement. OBJECTIVE: To review incretin physiology and the latest clinical data on glucagon-like peptide-1 (GLP-1) mimetics and dipeptidyl peptidase-IV (DPP-4) inhibitors and to use this as a foundation to discuss the practical issues of disease management, including clinical inertia, clinical recommendations, and evaluation of the best fit for incretin-based therapies in current treatment paradigms. SUMMARY: Clinical inertia is an important contributing factor to T2DM treatment failure and may be improved through more specific diagnosis, more complete patient education, and an emphasis on earlier and more aggressive therapy in goal-oriented fashion. Based largely on the underlying pathophysiology of T2DM, newer ACE/AACE guidelines have been developed to facilitate this more aggressive approach. The incretin-based therapies can favorably impact some underlying elements in T2DM pathophysiology, including glucagon hypersecretion, rapid gastric emptying, postprandial hyperglycemia, and, possibly, chronic -cell dysfunction. When incorporated early into a long-term, treat-to-target management plan, incretin-based therapies have the potential to reduce the prevalence of treatment failure in T2DM and may positively impact disease progression. CONCLUSIONS: Clinicians need to recognize and address the scope and impact of clinical inertia on T2DM patient outcomes. Better use of conventional treatment options and/or consideration of newer incretin-based therapies can contribute to improvements in patient health.",
author = "Triplitt, {Curtis L} and McGill, {Janet B.} and Daniel Porte and Conner, {Christopher S.}",
year = "2007",
month = "12",
language = "English (US)",
volume = "13",
journal = "Journal of managed care & specialty pharmacy",
issn = "2376-0540",
publisher = "Academy of Managed Care Pharmacy (AMCP)",
number = "9 Suppl C",

}

TY - JOUR

T1 - The changing landscape of type 2 diabetes

T2 - the role of incretin-based therapies in managed care outcomes.

AU - Triplitt, Curtis L

AU - McGill, Janet B.

AU - Porte, Daniel

AU - Conner, Christopher S.

PY - 2007/12

Y1 - 2007/12

N2 - BACKGROUND: The prevalence of diabetes is growing in the United States and, for many patients, blood glucose continues to be poorly managed. Significantly, more than half of people with type 2 diabetes mellitus (T2DM) have hemoglobin A1Cs greater than 7%. Several factors contribute to the failure to achieve treatment goals, including clinical inertia (the failure to initiate or advance therapy in a patient who is not at the evidence-based therapeutic goal) and failure to address all components of disease pathophysiology. Newer classes of antihyperglycemic agents, the incretin-based therapies, have the potential to improve goal achievement. OBJECTIVE: To review incretin physiology and the latest clinical data on glucagon-like peptide-1 (GLP-1) mimetics and dipeptidyl peptidase-IV (DPP-4) inhibitors and to use this as a foundation to discuss the practical issues of disease management, including clinical inertia, clinical recommendations, and evaluation of the best fit for incretin-based therapies in current treatment paradigms. SUMMARY: Clinical inertia is an important contributing factor to T2DM treatment failure and may be improved through more specific diagnosis, more complete patient education, and an emphasis on earlier and more aggressive therapy in goal-oriented fashion. Based largely on the underlying pathophysiology of T2DM, newer ACE/AACE guidelines have been developed to facilitate this more aggressive approach. The incretin-based therapies can favorably impact some underlying elements in T2DM pathophysiology, including glucagon hypersecretion, rapid gastric emptying, postprandial hyperglycemia, and, possibly, chronic -cell dysfunction. When incorporated early into a long-term, treat-to-target management plan, incretin-based therapies have the potential to reduce the prevalence of treatment failure in T2DM and may positively impact disease progression. CONCLUSIONS: Clinicians need to recognize and address the scope and impact of clinical inertia on T2DM patient outcomes. Better use of conventional treatment options and/or consideration of newer incretin-based therapies can contribute to improvements in patient health.

AB - BACKGROUND: The prevalence of diabetes is growing in the United States and, for many patients, blood glucose continues to be poorly managed. Significantly, more than half of people with type 2 diabetes mellitus (T2DM) have hemoglobin A1Cs greater than 7%. Several factors contribute to the failure to achieve treatment goals, including clinical inertia (the failure to initiate or advance therapy in a patient who is not at the evidence-based therapeutic goal) and failure to address all components of disease pathophysiology. Newer classes of antihyperglycemic agents, the incretin-based therapies, have the potential to improve goal achievement. OBJECTIVE: To review incretin physiology and the latest clinical data on glucagon-like peptide-1 (GLP-1) mimetics and dipeptidyl peptidase-IV (DPP-4) inhibitors and to use this as a foundation to discuss the practical issues of disease management, including clinical inertia, clinical recommendations, and evaluation of the best fit for incretin-based therapies in current treatment paradigms. SUMMARY: Clinical inertia is an important contributing factor to T2DM treatment failure and may be improved through more specific diagnosis, more complete patient education, and an emphasis on earlier and more aggressive therapy in goal-oriented fashion. Based largely on the underlying pathophysiology of T2DM, newer ACE/AACE guidelines have been developed to facilitate this more aggressive approach. The incretin-based therapies can favorably impact some underlying elements in T2DM pathophysiology, including glucagon hypersecretion, rapid gastric emptying, postprandial hyperglycemia, and, possibly, chronic -cell dysfunction. When incorporated early into a long-term, treat-to-target management plan, incretin-based therapies have the potential to reduce the prevalence of treatment failure in T2DM and may positively impact disease progression. CONCLUSIONS: Clinicians need to recognize and address the scope and impact of clinical inertia on T2DM patient outcomes. Better use of conventional treatment options and/or consideration of newer incretin-based therapies can contribute to improvements in patient health.

UR - http://www.scopus.com/inward/record.url?scp=41949084607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949084607&partnerID=8YFLogxK

M3 - Article

C2 - 18062735

AN - SCOPUS:41949084607

VL - 13

JO - Journal of managed care & specialty pharmacy

JF - Journal of managed care & specialty pharmacy

SN - 2376-0540

IS - 9 Suppl C

ER -